Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 126
Filtrar
1.
Cancer Genet ; 268-269: 46-54, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-36155382

RESUMO

It is well recognized that the primary KIT or PDGFRA variant of a gastrointestinal stromal tumour (GIST) can predict sensitivity to imatinib. However, these data are currently spread across a wide range of publications and have not been collated as one reference. A broad-ranging literature search was therefore performed to assemble such a database which should help optimize imatinib-based management of GIST patients henceforth. Having excluded wild type GISTs and results for imatinib used as adjuvant therapy, 79 publications (dated August 2001 to March 2022) underwent data extraction. These data on imatinib sensitivity were either derived from in vitro studies, predicted by in silico analysis or based on in vivo clinical patient response. Data interpretation carried some caveats: there was a potential for replication of patient-derived data between older and new publications; only predicted protein sequences were presented; the criteria used to record clinical response were not uniform across all publications; and imatinib dosage could vary between different clinical publications. However, these data showed broad agreement of imatinib sensitivity amongst similar subtypes of KIT or PDGFRA variant. There was also agreement between in vivo versus in vitro/in silico derived sensitivity data for most variants when both data types were available.


Assuntos
Antineoplásicos , Tumores do Estroma Gastrointestinal , Humanos , Mesilato de Imatinib/uso terapêutico , Tumores do Estroma Gastrointestinal/tratamento farmacológico , Tumores do Estroma Gastrointestinal/genética , Receptor alfa de Fator de Crescimento Derivado de Plaquetas/genética , Proteínas Proto-Oncogênicas c-kit/genética , Benzamidas/uso terapêutico , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Antineoplásicos/uso terapêutico , Mutação
2.
BJS Open ; 6(4)2022 07 07.
Artigo em Inglês | MEDLINE | ID: mdl-36029031

RESUMO

AIMS: Recent data suggest that the incidence of malignant appendiceal tumours is increasing. This study aimed to determine temporal trends in the incidence of malignant appendiceal tumours within England and a possible influence by demographic factors. METHODS: All incident cases of appendiceal tumours in patients aged 20 years and above were identified from the National Cancer Registration and Analysis Service database between 1995 and 2016 using ICD-9/10 codes. Cancers were categorized according to histology. Joinpoint regression analysis was used to investigate changes in age-standardized incidence rates by age, sex, histological subtype and index of multiple deprivation quintiles, based on socioeconomic domains (income, employment, education, health, crime, barriers to housing and services and living environment). Average annual per cent changes (AAPCs) were estimated by performing Monte-Carlo permutation analysis. RESULTS: A total of 7333 tumours were diagnosed and 7056 patients were analysed, comprising 3850 (54.6 per cent) neuroendocrine tumours (NETs), 1892 (26.8 per cent) mucinous adenocarcinomas and 1314 (18.6 per cent) adenocarcinoma (not otherwise specified). The overall incidence of appendiceal tumours increased from 0.3 per 100 000 to 1.6 per 100 000 over the study interval. Incidence rate increases of comparable magnitude were observed across all age groups, but the AAPC was highest among patients aged 20-29 years (15.6 per cent, 95 per cent c.i 12.7-18.6 per cent) and 30-39 years (14.2 per cent, 12.2-16.2 per cent) and lowest among those aged 70-79 years (6.8 per cent, 5.7-8.0 per cent). Similar incidence rate increases were reported across all socioeconomic deprivation quintiles and in both sexes. Analysis by grade of NET showed that grade 1 tumours accounted for 63 per cent between 2010 and 2013, compared with 2 per cent between 2000 and 2003. CONCLUSIONS: The incidence rate of malignant appendiceal tumours has increased significantly since 1995 and is mainly attributed to an increase in NETs. The increased diagnosis of low-grade NETs may in part be due to changes in pathological classification systems.


Assuntos
Adenocarcinoma , Neoplasias do Apêndice , Tumores Neuroendócrinos , Inglaterra , Feminino , Humanos , Incidência , Masculino
3.
J Clin Pathol ; 75(8): 519-524, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35853655

RESUMO

Gastrointestinal (GI) tract pathology represents one of the largest individual specialties within cellular pathology departments globally. As with other specialties, clear communication with clinicians providing primary care for the patient is of utmost importance for optimal management and for appropriate use of resources such as endoscopy. A wide breadth of neoplastic and inflammatory conditions afflicts the GI tract. Here, we aim to illustrate how pathology reporting of GI tract specimens influences patient management and specifically how precise reporting of key parameters in different specimen types and different disease processes can directly impact patient care. We describe the potential clinical relevance of selected pathology data items pertinent to specific conditions and highlight areas of contention with respect to the significance of some pathology features. Recent guidelines are described where a change, for example, in diagnostic criteria for a condition is described, or criteria influencing further management such as endoscopic surveillance. The aim of this review is to focus on the clinical importance of careful written communication between the pathologist and primary clinician, illustrated by selective clinical scenarios involving the upper and lower GI tracts.


Assuntos
Trato Gastrointestinal , Patologistas , Endoscopia Gastrointestinal , Humanos
4.
Histopathology ; 81(3): 402-406, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35758180

RESUMO

AIMS & METHODS: Simple biliary cysts of the liver are described to be lined by biliary epithelium and may be managed nonsurgically or by deroofing only. By contrast, its important differential diagnosis-mucinous cystic neoplasm (MCN)-is at least focally lined by mucinous epithelium, has malignant potential, and therefore should be resected. Following anecdotal observations in routine diagnostic practice, the following case series was assembled to confirm whether simple biliary cysts of the liver can be lined by mucinous epithelium. Detailed clinicoradiological review, including postoperative follow-up, was also completed to assess whether the presence of mucinous epithelium had any associations, including a risk of hepatobiliary neoplasia. RESULTS: Histological review of 21 simple biliary cysts received as surgical specimens over a 3- year period confirmed an absence of ovarian-like stroma in all cases. The lining epithelium of seven cysts showed focal supranuclear/apical mucin, as confirmed histochemically. Cysts with mucinous epithelium were generally larger and more often showed histological evidence of previous haemorrhage than cysts without this epithelium. There were no other statistically-significant differences in clinicoradiological features between cysts with and without mucinous epithelium, including at postoperative radiological follow-up. CONCLUSIONS: Focal mucinous epithelium can be present in at least one-third of surgically-managed, simple biliary cysts of the liver. Such epithelium may be metaplastic and should not be misinterpreted to indicate a diagnosis of MCN but, apart from this, appears to have no clinical significance. Ovarian-like stroma may therefore be the only histological feature that reliably distinguishes MCN from simple biliary cyst.


Assuntos
Cistos , Doenças da Vesícula Biliar , Neoplasias Hepáticas , Neoplasias Pancreáticas , Diagnóstico Diferencial , Epitélio/patologia , Doenças da Vesícula Biliar/diagnóstico , Humanos , Neoplasias Hepáticas/patologia , Neoplasias Pancreáticas/patologia
5.
Primates ; 63(3): 283-291, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35218456

RESUMO

The transformation and depletion of primary forest over the past few decades have placed almost half of the world's primate species under the threat of extinction. Developing any successful conservation program for primates requires distribution and demography data, as well as an understanding of the relationships between these factors and their habitat. Between March and June 2010 and 2011 we collected data on the presence and demographic parameters of howler and spider monkeys by carrying out surveys, and validated our findings using local knowledge. We then examined the relationship between forest type and the presence of these primates at 54 sites in the northern area of the Selva Zoque Corridor, Mexico. We detected 86 spider monkey groups across 31 plots and censused 391 individuals (mean ± SD = 5.9 ± 3.0 individuals per sub-group, n = 67 sub-groups). We also detected 69 howler monkey groups across 30 plots and censused 117 individuals (mean ± SD = 5.3 ± 2.4 individuals per group, n = 22 groups). Howler monkey presence was not related to any specific vegetation type, while spider monkeys were present in areas with a higher percentage of tall forest (trees > 25 m high). Overall, spider monkeys were more prevalent than howler monkeys in our sampling sites and showed demographic characteristics similar to those in better protected areas, suggesting that the landscape features in the Uxpanapa Valley are suitable for their needs. Conversely, howler monkey presence was found to be more limited than in other regions, possibly due to the extended presence of spider monkeys.


Assuntos
Alouatta , Atelinae , Animais , Florestas , Prevalência , Floresta Úmida
6.
Histopathology ; 80(5): 782-789, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-34773294

RESUMO

AIMS: The inception of the National Health Service Bowel Cancer Screening Programme in England in 2006 highlighted the fact that the differential diagnosis between the presence of epithelial misplacement and adenocarcinoma occurring in colorectal adenomas is problematic. The pathology Expert Board (EB) was created to facilitate the review of difficult cases by a panel of three experienced gastrointestinal pathologists. This article describes a review of the work of the EB over a 4-year period (2017-2020). METHODS AND RESULTS: Four hundred and thirty polyps were referred to the EB from 193 pathologists and 76 hospitals during this time. The EB diagnosis was benign for 67%, malignant for 28%, and equivocal for 2% (with no consensus in the remainder). The most common diagnosis change made by the EB was from malignant to benign-made in 50% of polyps referred with an initially malignant diagnosis. The level of agreement between the individual EB members was 'good' (kappa score of 0.619) but that between the EB and the referring diagnosis was 'poor' (kappa score of 0.149). Data from one EB member indicated that the presence of lamina propria, features of torsion and cytological similarity between the superficial and deep glands were predictors of a benign diagnosis, whereas the presence of irregular neoplastic glands, a desmoplastic reaction and lymphovascular invasion were commonly observed features in polyps with a malignant diagnosis. CONCLUSION: Diagnostic agreement between EB members is better than that between the EB and referring pathologists. There was a consistent trend for the EB to change diagnoses from malignant to benign.


Assuntos
Detecção Precoce de Câncer , Prova Pericial , Neoplasias Intestinais/diagnóstico , Neoplasias Intestinais/patologia , Pólipos Intestinais/diagnóstico , Pólipos Intestinais/patologia , Patologistas , Adenocarcinoma/diagnóstico , Adenocarcinoma/patologia , Diagnóstico Diferencial , Inglaterra , Humanos , Mucosa Intestinal/patologia , Encaminhamento e Consulta
7.
J Clin Pathol ; 75(3): 205-208, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33509947

RESUMO

AIMS AND METHODS: Faecal calprotectin (FCP) measurement is used especially to investigate for inflammatory bowel disease (IBD). To assess the utility of sampling endoscopically normal large bowel among patients first presenting with elevated FCP, this study identified 115 such patients out of 652 patients with elevated FCP from approximately 6000 primary care tests processed over 15 months. RESULTS: 23 cohort patients showed histologically abnormal large bowel biopsies. Only four cases demonstrated acute inflammation and two such patients only showed scattered cryptitis and did not develop IBD. A third patient demonstrated similar histology but, following repeat colonoscopy, her elevated FCP was attributed to small intestinal inflammation. Only the fourth patient's large bowel biopsies showed features suggesting Crohn's disease, but this represented an IBD detection rate out of 115 sets of large bowel biopsies of 0.9%. CONCLUSIONS: Sampling of endoscopically normal large bowel among patients first presenting with elevated FCP is not clinically justified.


Assuntos
Doença de Crohn/diagnóstico , Doenças Inflamatórias Intestinais/diagnóstico , Adulto , Biomarcadores/análise , Estudos de Coortes , Colonoscopia , Doença de Crohn/patologia , Fezes/química , Feminino , Humanos , Inflamação , Doenças Inflamatórias Intestinais/patologia , Mucosa Intestinal/patologia , Complexo Antígeno L1 Leucocitário/análise , Masculino , Pessoa de Meia-Idade , Manejo de Espécimes , Adulto Jovem
9.
Histopathology ; 79(2): 252-259, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-33657658

RESUMO

AIMS: Because serous cystadenoma (SCA) does not usually require excision, it is critical to distinguish it from differential diagnoses which do, especially neuroendocrine tumour (NET). The gold standard for diagnosing SCA is assessment of endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNAB) material. Inhibin immunohistochemistry aids this assessment, but such positivity is not absolutely sensitive or specific to SCA. The following is the largest known study of SCA EUS-FNAB specimens and the first to compare four potential SCA immunomarkers between themselves and inhibin, compared against NET. METHODS AND RESULTS: Immunohistochemistry for calponin, mucin 6 (MUC6), glucose transporter 1 (GLUT1) and vascular endothelial growth factor A (VEGFA) was performed on 30 EUS-FNAB and three resection specimens of SCA and 32 EUS-FNAB specimens of NET. GLUT1 and VEGFA were suboptimal as diagnostic immunomarkers of SCA, being expressed by 10 and 44% of NETs, respectively. Further, their expression by cellular constituents of blood which often contaminate EUS-FNAB specimens hampered identification of neoplastic cells, especially in hypocellular samples. While 19% of NETs showed nuclear MUC6 positivity, cytoplasmic expression of the protein showed 100% specificity and sensitivity as an SCA marker. However, assessing MUC6 in EUS-FNAB specimens must also consider the protein's focal expression in physiological pancreatic, gastric or duodenal tissues, which can contaminate these specimens. Calponin was less sensitive (71% versus 100%) but more specific (100% versus 91%) than inhibin, although easier to assess in EUS-FNAB specimens than MUC6. CONCLUSIONS: Of the four potential immunomarkers of SCA suggested by the existing literature, calponin and MUC6 are useful complementary studies to inhibin for application to EUS-FNAB specimens.


Assuntos
Proteínas de Ligação ao Cálcio/metabolismo , Cistadenoma Seroso/diagnóstico , Cistadenoma Seroso/imunologia , Aspiração por Agulha Fina Guiada por Ultrassom Endoscópico , Inibinas/metabolismo , Proteínas dos Microfilamentos/metabolismo , Mucina-6/metabolismo , Adolescente , Adulto , Idoso , Biomarcadores Tumorais , Proteínas de Ligação ao Cálcio/imunologia , Estudos de Coortes , Cistadenoma Seroso/patologia , Duodeno/patologia , Aspiração por Agulha Fina Guiada por Ultrassom Endoscópico/instrumentação , Feminino , Transportador de Glucose Tipo 1/metabolismo , Humanos , Imuno-Histoquímica , Inibinas/imunologia , Masculino , Proteínas dos Microfilamentos/imunologia , Pessoa de Meia-Idade , Tumores Neuroendócrinos/patologia , Pâncreas/patologia , Estômago/patologia , Sinaptofisina/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo
10.
Histopathology ; 78(5): 772-777, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33217036

RESUMO

AIMS: The diagnostic and clinical significance of granulomas in gastrointestinal (GI) biopsies from haematopoietic transplant patients remains disputed, especially following the proposal of cord colitis syndrome (CCS) as a new entity. The aim of the following study was to explore this controversy by identifying such biopsies with granulomas and detailing their clinicopathological associations. METHODS AND RESULTS: Twelve patients with granuloma-containing biopsies were identified from across three scenarios: prospectively during a GI pathologist's routine practice over a period of 5 years; retrospectively from a cohort of transplant patients with clinically validated GI graft versus host disease (GVHD); and retrospectively from a cohort of patients who had received umbilical cord blood (UCB). Their clinicopathological assessments (which included unique long-term patient follow-up) showed that granulomas are only rarely seen across all GI biopsies from haematopoietic transplant patients, and may uncommonly constitute a histological feature of GI GVHD. Granulomas-and especially well-defined, non-cryptolytic ones-are more commonly present in GI biopsies from UCB recipients, but do not show any accompanying histological features that are different from those seen in granuloma-containing biopsies from other patient groups. Furthermore, the three UCB recipients with granuloma-containing biopsies were clinically diagnosed with GVHD rather than CCS. Finally, polymorphic post-transplant lymphoproliferative disorder (PTLD) can present histologically as GI granulomatous inflammation that mimics Crohn's disease. CONCLUSIONS: Granulomas in GI biopsies of haematopoietic transplant patients may often indicate a treatable aetiology such as GVHD or PTLD. Granulomas are more commonly seen in GI biopsies from UCB recipients, but do not necessarily indicate a diagnosis of CCS.


Assuntos
Biópsia , Granuloma , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Adulto , Idoso , Transplante de Células-Tronco de Sangue do Cordão Umbilical/efeitos adversos , Doença de Crohn/diagnóstico , Doença de Crohn/patologia , Diagnóstico Diferencial , Feminino , Trato Gastrointestinal/patologia , Doença Enxerto-Hospedeiro/diagnóstico , Doença Enxerto-Hospedeiro/patologia , Granuloma/diagnóstico , Granuloma/patologia , Humanos , Transtornos Linfoproliferativos/diagnóstico , Transtornos Linfoproliferativos/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
11.
J Clin Pathol ; 74(3): 194-197, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32646927

RESUMO

AIM: There is no known specific biomarker or genetic signal for quadruple wild-type (qWT) gastrointestinal stromal tumours (GISTs). By next-generation sequencing (NGS) of different GIST subgroups, this study aimed to characterise such a biomarker especially as a potential therapeutic target. METHODS AND RESULTS: An NGS panel of 672 kinase genes was applied to DNA extracted from 11 wild-type GISTs (including three qWT GISTs) and 5 KIT/PDGFRA mutated GISTs. Short variants which were present in qWT GISTs but no other GIST subgroup were shortlisted. After removing common population variants, in silico-classified deleterious variants were found in CSNK2A1, MERTK, RHEB, ROCK1, PIKFYVE and TRRAP. None of these variants were demonstrated in a separate cohort of four qWT GISTs. CONCLUSIONS: Short kinase variants which are specific to qWT GISTs are rare and are not universally demonstrated by this whole subgroup. It is therefore possible that the current definition of qWT GIST still covers a heterogenous population.


Assuntos
Tumores do Estroma Gastrointestinal/genética , Variação Genética , Fosfotransferases/genética , Adolescente , Adulto , Idoso , Estudos de Coortes , Feminino , Formaldeído , Tumores do Estroma Gastrointestinal/classificação , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Pessoa de Meia-Idade , Inclusão em Parafina , Adulto Jovem
12.
Histopathology ; 78(4): 634-639, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33001486

RESUMO

AIMS: Accurate and consistent pathological staging of colorectal carcinoma (CRC) in resection specimens is especially crucial to guide adjuvant therapy. The aim of this study was to assess whether certain staging scenarios yield discordant opinions in the setting of current international and UK national guidelines. METHODS AND RESULTS: Members of the UK Gastrointestinal Pathology External Quality Assurance Scheme were invited to complete an anonymous, on-line survey that presented 15 scenarios related to pT or pR staging of CRC, and three questions about the respondent. The survey invitation was e-mailed to 405 pathologists, and 184 (45%) responses were received. The respondents had discordant opinions on whether and how CRC pT or pR staging is affected by: acellular mucin lakes and duration after short-course radiotherapy; the nature of the carcinoma at a resection margin or peritoneal surface; and microscopic evidence of perforation. This discordance was rarely related to the respondent's occupation type, and was not related to duration of work as a consultant or the staging guidelines used. CONCLUSIONS: This survey confirms that there remain several clinically critical but unresolved pT and pR staging issues for CRC. These issues therefore deserve attention in future versions of international and national staging guidelines.


Assuntos
Carcinoma/patologia , Neoplasias Colorretais/patologia , Humanos , Estadiamento de Neoplasias , Patologistas , Inquéritos e Questionários
13.
J Clin Pathol ; 73(6): 297-309, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31964682

RESUMO

Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB) is the optimal method for sampling lesions of the pancreas. This procedure is being performed at increasing numbers of hospitals and therefore, more and more cellular pathology departments are having to process and report EUS-FNAB specimens. This article outlines the advantages of using tissue/cell block preparation to process these specimens. In particular, such preparation concentrates, conserves and preserves sampled material which is then available for a full array of further analyses. Tissue/cell block preparation also enables EUS-FNAB specimens to be assessed by a wider range of cellular pathologists. This article demonstrates how a tissue/cell block protocol permits the diagnosis of the full range of pancreatic pathologies sampled by EUS-FNAB. The protocol is identical for all these pathologies (including both solid and cystic lesions) and is simple at all stages of the specimen pathway, from collection to processing to assessment.


Assuntos
Aspiração por Agulha Fina Guiada por Ultrassom Endoscópico/métodos , Pancreatopatias/diagnóstico , Manejo de Espécimes , Humanos , Pâncreas/patologia , Pancreatopatias/patologia
14.
J Clin Pathol ; 73(2): 102-106, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31462450

RESUMO

AIMS: The cell block technique for assessing endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) specimens from pancreatic mucinous cystic lesions (MCLs) was systematically evaluated for the first time, including comparisons with three traditional methods of assessing such specimens. METHODS: The prospective arm comprised EUS-FNA specimens from EUS-suspected pancreatic MCLs. The retrospective arm comprised EUS-FNA specimens from pancreatic MCLs surgically resected before the study start. For each specimen, these data points were collected: macroscopic likelihood of mucin, cyst fluid carcinoembryonic antigen (CEA) level and presence of mucin in air-dried, direct smears and in cell block preparations. RESULTS: The prospective and retrospective arms of the study comprised 80 and 30 EUS-FNA specimens, respectively. Seven prospective cases led to surgical resections during the study, and therefore, 37 EUS-FNA specimens were confirmed to have originated from MCLs. In the prospective arm, macroscopic mucin was suspected, cyst fluid CEA level exceeded 192 ng/mL, mucin was detected in direct smears and cell block preparations in 78%, 30%, 39% and 73% of cases, respectively. Of the 37 specimens confirmed to originate from MCLs, macroscopic mucin assessment, cyst fluid CEA level, direct smear mucin assessment and cell block mucin assessment had sensitivities for diagnosing MCL of 87%, 45%, 45% and 81%, respectively. CONCLUSIONS: Cell block preparations are as likely to identify mucin from pancreatic MCLs as macroscopic assessment but are twice as likely to diagnose MCL than direct smears and fluid CEA biochemistry. The cell block technique is easy for sample collection and processing especially because these are identical for solid and cystic pancreatic lesions.


Assuntos
Aspiração por Agulha Fina Guiada por Ultrassom Endoscópico , Mucinas/análise , Cisto Pancreático/química , Cisto Pancreático/patologia , Inclusão em Parafina , Biomarcadores/análise , Antígeno Carcinoembrionário/análise , Humanos , Cisto Pancreático/cirurgia , Valor Preditivo dos Testes , Estudos Prospectivos , Reprodutibilidade dos Testes , Estudos Retrospectivos , Fixação de Tecidos
16.
J Clin Pathol ; 72(8): 562-565, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31097491

RESUMO

AIMS: This case series intends to expand currently limited knowledge regarding the existence and diagnostic significance of intramucosal fat in colorectal polyps. METHODS: Clinicopathological features of nine such polyps were reported following histopathological review, including S100 and EMA immunohistochemistry. RESULTS AND CONCLUSIONS: Such review subdivided seven polyps into three groups: (1) mucosal perineurioma/serrated polyps with fat among the perineurial stroma (three cases); (2) submucosal lipomas with adipose tissue extending into the overlying mucosa (two cases) and (3) polyps with intramucosal adipose tissue only, that is, the newly described but less-recognised entity known as intramucosal lipoma (two cases). The two remaining polyps of this series did not include submucosa but, from assessing their muscularis mucosae, were favoured to represent intramucosal lipomas. The first two phenomena are formally described for the first time by this case series. The last of these three diagnoses should prompt investigations for Cowden syndrome, but intramucosal lipomas are more often sporadic/non-syndromic.


Assuntos
Tecido Adiposo/patologia , Pólipos do Colo/patologia , Neoplasias Colorretais/patologia , Mucosa Intestinal/patologia , Pólipos Intestinais/patologia , Lipoma/patologia , Doenças Retais/patologia , Idoso , Pólipos do Colo/química , Neoplasias Colorretais/química , Diagnóstico Diferencial , Feminino , Humanos , Imuno-Histoquímica , Mucosa Intestinal/química , Pólipos Intestinais/química , Lipoma/química , Masculino , Pessoa de Meia-Idade , Mucina-1/análise , Valor Preditivo dos Testes , Doenças Retais/metabolismo , Proteínas S100/análise
17.
Appl Immunohistochem Mol Morphol ; 27(6): 461-465, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-29734250

RESUMO

A unique cohort of chemo-naive gastrointestinal stromal tumors (GISTs) with double-primary tyrosine kinase mutations was characterized particularly to determine whether coexistent mutations represent a single mutational event. Up to 2013, 4 UK centers reported 9 GISTs with 2 primary tyrosine kinase mutations. In each of 8 cases validated by next generation sequencing, both mutations were present in the same allele of the same exon (KIT exon 11 or 17, or PDGFRA exon 18). One case showed the second mutation only on some of the mutant alleles. Seven cases showed both mutations in all the reads, but in 2 cases, additional variants were found only in some reads. Clinicopathologic features of the 8 cases were similar to GISTs with single-primary mutations. When GIST genotyping rarely uncovers multiple tyrosine kinase variants in an exon, they occur in the same allele but are likely to represent separate mutational events and lack clinical significance.


Assuntos
Éxons/genética , Neoplasias Gastrointestinais/diagnóstico , Tumores do Estroma Gastrointestinal/diagnóstico , Genótipo , Mutação/genética , Proteínas Proto-Oncogênicas c-kit/genética , Receptor alfa de Fator de Crescimento Derivado de Plaquetas/genética , Alelos , Estudos de Coortes , Feminino , Tumores do Estroma Gastrointestinal/genética , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Pessoa de Meia-Idade , Patologia Molecular
19.
Histopathology ; 73(1): 157-161, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29464744

RESUMO

AIMS: The currently recognised subtypes of anal canal/peri-anal adenocarcinoma are those arising from low rectal mucosa or columnar cuff, fistula-related tumours and anal gland carcinoma. This report presents two examples of a hitherto undescribed subtype of peri-anal adenocarcinoma with an intestinal phenotype. METHODS AND RESULTS: A 74-year-old man had a peri-anal tumour locally excised, whereas a 73-year-old female underwent an abdominoperineal resection for peri-anal Paget's disease with an underlying carcinoma. Neither patient had a history of perineal fistulae, Crohn's disease or previous gastrointestinal neoplasia, and neither showed clinical, radiological or endoscopic evidence of another abdominal or pelvic tumour. Both resection specimens contained adenocarcinoma, which were similar in demonstrating an intestinal morphology and CDX2 immunopositivity. The man has shown a disease-free outcome thus far, but the woman has suffered with nodal and pelvic recurrence within a few months of surgery. CONCLUSIONS: The name 'primary peri-anal adenocarcinoma of intestinal type' is proposed for this previously unrecognised subtype of perineal neoplasia. Awareness of its distinct existence - by recognising its intestinal morphology and immunophenotype while excluding metastasis from the intestinal tract - should help to collate data to determine its specific prognosis and to formulate its best management.


Assuntos
Adenocarcinoma/patologia , Neoplasias do Ânus/patologia , Idoso , Feminino , Humanos , Mucosa Intestinal/patologia , Masculino
20.
J Clin Pathol ; 71(5): 388-394, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29439009

RESUMO

The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.


Assuntos
Adenocarcinoma/enzimologia , Biomarcadores Tumorais/análise , Neoplasias Esofágicas/enzimologia , Junção Esofagogástrica/enzimologia , Imuno-Histoquímica/normas , Técnicas de Diagnóstico Molecular/normas , Patologia Clínica/métodos , Patologia Molecular/normas , Receptor ErbB-2/análise , Sociedades Médicas/normas , Neoplasias Gástricas/enzimologia , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/genética , Adenocarcinoma/patologia , Antineoplásicos Imunológicos/uso terapêutico , Biomarcadores Tumorais/genética , Biópsia/normas , Tomada de Decisão Clínica , Consenso , Neoplasias Esofágicas/tratamento farmacológico , Neoplasias Esofágicas/genética , Neoplasias Esofágicas/patologia , Junção Esofagogástrica/efeitos dos fármacos , Junção Esofagogástrica/patologia , Humanos , Terapia de Alvo Molecular , Medicina de Precisão/normas , Valor Preditivo dos Testes , Receptor ErbB-2/antagonistas & inibidores , Receptor ErbB-2/genética , Reprodutibilidade dos Testes , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/genética , Neoplasias Gástricas/patologia , Trastuzumab/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...